PAVmed (PAVM) Price & Analysis

Compare

654 Followers

PAVM Stock Chart & Stats

$0.29

-$0.02(-2.96%)

At close: Jan 08 4:00 PM EST

$0.29

-$0.02(-2.96%)

Day’s Range― - ―

52-Week Range$6.00 - $26.82

Previous CloseN/A

Volume127.06K

Average Volume (3M)377.79K

Market Cap

$9.30M

Enterprise Value$15.47M

Total Cash (Recent Filing)$3.10M

Total Debt (Recent Filing)$9.28M

Price to Earnings (P/E)―

Beta1.30

Next Earnings

Mar 31, 2026

EPS Estimate

-5.4

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-8.70

Shares Outstanding1,063,150

10 Day Avg. Volume774,204

30 Day Avg. Volume377,786

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)-2.43

Price to Sales (P/S)2.03

P/FCF Ratio-0.18

Enterprise Value/Market Cap1.66

Enterprise Value/Revenue533.35

Enterprise Value/Gross Profit-79.73

Enterprise Value/Ebitda9.61

Forecast

1Y Price Target

$17.00

Price Target Upside5762.07% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Corporate Strategy And ValuationLaunch of the PMX incubator combined with an analyst move to a higher 12-month price target signals potential for new asset creation and perceived upside beyond core device sales.

Medicare ReimbursementImminent Medicare coverage expected in 2026 for procedures tied to Lucid's platform could expand reimbursement pathways for PAVmed technologies, supporting broader patient access and revenue growth.

Strategic Partnerships And Digital HealthStrategic partnership with The Ohio State's James Cancer Hospital to pilot Veris Health's personalized digital cancer-care tools and development of a biopharma companion module targeting FDA clearance may validate clinical utility and accelerate adoption alongside new oncology therapeutics.

Bears Say

Competitive RiskProlonged commercialization challenges could enable competitors to capture market share, limiting revenue upside even if PAVmed's products eventually reach the market.

Development And Regulatory RiskOngoing development and regulatory hurdles for PAVmed's devices create execution risk that could delay product approvals and market entry, weighing on near-term growth expectations.

Financing And Dilution RiskExtended development timelines may increase financing needs, raising the risk of equity dilution or costly capital raises that can pressure the stock.

PAVmed News

PAVmed trading halted, news pending

19:50 EST PAVmed (PAVM) trading halted, news pending Published first on TheFly – the ultimate source for real-time,...

17d ago

PAVM

PAVmed announces 1-for-30 reverse stock split

PAVmed (PAVM) announced it will conduct a 1-for-30 reverse stock split of its common stock. The reverse stock...

18d ago

PAVM

PAVmed Announces Reverse Stock Split to Maintain Nasdaq Listing

PAVmed ( ($PAVM) ) has issued an announcement. On December 30, 2025, PAVmed Inc. announced that it will...

18d ago

PAVM

Lucid Diagnostics’ esophageal precancer detection tools show efficacy in study

Lucid Diagnostics (LUCD), a subsidiary of PAVmed (PAVM), announced new data from the largest reported real-world experience of...

1M ago

LUCD

PAVM

PAVmed Approves Reverse Stock Split Amendment

PAVmed ( ($PAVM) ) has issued an update. On December 5, 2025, PAVmed Inc. held a special meeting...

1M ago

PAVM

Pavmed Inc. Reports Q3 2025 Earnings and Strategic Focus

Pavmed ( ($PAVM) ) has released its Q3 earnings. Here is a breakdown of the information Pavmed presented...

2M ago

PAVM

PAVmed’s Earnings Call: Triumphs and Trials

Pavmed (($PAVM)) has held its Q3 earnings call. Read on for the main highlights of the call. PAVmed’s...

2M ago

PAVM

PAVM Upcoming Earnings Report: What to Expect?

Pavmed (PAVM) is scheduled to report 3rd quarter earnings on 11/18/2025. Regarding Q3 estimates, Wall Street analysts expect...

2M ago

PAVM

PAVmed Announces Q3 2025 Financial Results and Updates

PAVmed ( ($PAVM) ) has shared an announcement. On November 13, 2025, PAVmed Inc. announced a business update...

2M ago

PAVM

PAVmed’s Lucid Diagnostics Completes Public Stock Offering

The latest update is out from PAVmed ( ($PAVM) ). On September 11, 2025, Lucid Diagnostics Inc., a...

4M ago

PAVM

PAVmed to license esophageal imaging technology from Duke Technology

PAVmed (PAVM) has executed a non-binding letter of intent with Duke University to license, through a newly-formed subsidiary,...

5M ago

PAVM

PAVmed Reports Q2 2025 Financial Results and Developments

The latest update is out from PAVmed ( ($PAVM) ). In its second quarter of 2025, PAVmed Inc....

5M ago

PAVM

PAVmed reports Q2 non-GAAP EPS (5c) vs. (84c) last year

Reports Q2 revenue $6K vs. $979K last year. PAVmed (PAVM) had cash and cash equivalents of $4.0M as...

5M ago

PAVM

Lucid Diagnostics Reports Q2 2025 Financial Results

Pavmed ( ($PAVM) ) has released its Q2 earnings. Here is a breakdown of the information Pavmed presented...

5M ago

PAVM

PAVM FAQ

What was PAVmed Inc’s price range in the past 12 months?

PAVmed Inc lowest stock price was $6.00 and its highest was $26.82 in the past 12 months.

What is PAVmed Inc’s market cap?

PAVmed Inc’s market cap is $9.30M.

When is PAVmed Inc’s upcoming earnings report date?

PAVmed Inc’s upcoming earnings report date is Mar 31, 2026 which is in 73 days.

How were PAVmed Inc’s earnings last quarter?

PAVmed Inc released its earnings results on Nov 13, 2025. The company reported -$8.7 earnings per share for the quarter, missing the consensus estimate of -$5.1 by -$3.6.

Is PAVmed Inc overvalued?

According to Wall Street analysts PAVmed Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does PAVmed Inc pay dividends?

PAVmed Inc does not currently pay dividends.

What is PAVmed Inc’s EPS estimate?

PAVmed Inc’s EPS estimate is -5.4.

How many shares outstanding does PAVmed Inc have?

PAVmed Inc has 1,063,150 shares outstanding.

What happened to PAVmed Inc’s price movement after its last earnings report?

PAVmed Inc reported an EPS of -$8.7 in its last earnings report, missing expectations of -$5.1. Following the earnings report the stock price went down -8.534%.

Which hedge fund is a major shareholder of PAVmed Inc?

Currently, no hedge funds are holding shares in PAVM

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

PAVmed Inc

PAVmed Inc. is a medical technology company focused on the development and commercialization of innovative medical devices and diagnostic tools. Operating primarily in the healthcare sector, PAVmed aims to improve patient outcomes through its core products, which include devices for gastroenterology, urology, and other specialty areas. The company is known for its commitment to addressing unmet medical needs with solutions that enhance clinical workflows and patient care.

PAVmed (PAVM) Earnings & Revenues

Historic Earnings Reports

PAVM Company Deck

PAVM Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call highlighted several significant achievements, including successful Medicare endorsement for EsoGuard, strong financial positioning for Lucid, and strategic partnerships for Veris. However, challenges remain in debt restructuring and stagnant EsoGuard revenue growth.View all PAVM earnings summaries

PAVM Stock 12 Month Forecast

Average Price Target

$17.00

▲(5762.07% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","34":"$34","12.25":"$12.25","19.5":"$19.5","26.75":"$26.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,12.25,19.5,26.75,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.62,7.418461538461538,8.216923076923077,9.015384615384615,9.813846153846153,10.612307692307692,11.41076923076923,12.209230769230768,13.007692307692306,13.806153846153844,14.604615384615382,15.40307692307692,16.201538461538462,{"y":17,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.62,7.418461538461538,8.216923076923077,9.015384615384615,9.813846153846153,10.612307692307692,11.41076923076923,12.209230769230768,13.007692307692306,13.806153846153844,14.604615384615382,15.40307692307692,16.201538461538462,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.62,7.418461538461538,8.216923076923077,9.015384615384615,9.813846153846153,10.612307692307692,11.41076923076923,12.209230769230768,13.007692307692306,13.806153846153844,14.604615384615382,15.40307692307692,16.201538461538462,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.81,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":33.3,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.82,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":21,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":24.6,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.3,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":18.48,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":15.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.2,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.87,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":10.59,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 48, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.62,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >